Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Heather Burnett, Kyle Fahrbach, Allie Cichewicz, Ramandeep Jindal, Jialu Tarpey, Adeline Durand, Maximiliano Di Domenico, Andreas Reichelt & Adie Viljoen. (2022) Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Current Medical Research and Opinion 38:5, pages 777-784.
Read now
Read now
Bernd Eber, Dominik Lautsch, Christiane Fauer, Heinz Drexel, Karl Peter Pfeiffer, Otto Traindl & Max Pichler. (2012) Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Current Medical Research and Opinion 28:9, pages 1447-1454.
Read now
Read now
Jui-Chu Huang, Tao-Yu Lee, Miaw-Jene Liou, Chi-Min Lin, Dee Pei, Zhih-Cherng Chen, Rue-Tsuan Liu & Ching-Fai Kwok. (2011) Begin with the Real-world Patients of Non-goal-achieved Hypercholesterolemia in Taiwan through the Ezetimibe/Simvastatin Tablet – The BRAVO Study. Current Medical Research and Opinion 27:8, pages 1645-1651.
Read now
Read now
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 27:6, pages 1191-1210.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
Nkechinyere Ijioma & Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, pages 131-145.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
A. H. Liem, A. P. van de Woestijne, A. H. Zwinderman, F. L. J. Visseren & J. W. Jukema. (2008) Determinants of CRP level in statin-treated patients. Current Medical Research and Opinion 24:4, pages 1065-1068.
Read now
Read now
Articles from other publishers (24)
Qian Xu, Yiming Deng, Jun Xiao, Xiangrui Liu, Min Zhou, Zhong Ren, Juan Peng, Yaling Tang, Zhisheng Jiang, Zhihan Tang & Lushan Liu. (2021) Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. Current Medicinal Chemistry 28:5, pages 1025-1041.
Crossref
Crossref
Shahin Alizadeh-Fanalou, Ali Nazarizadeh, Fatemeh Alian, Parisa Faraji, Bahareh Sorori & Mohsen Khosravi. (2020) Small dense low-density lipoprotein-lowering agents. Biological Chemistry 401:10, pages 1101-1121.
Crossref
Crossref
Vicki Vania, Lu Wang, Marco Tjakra, Tao Zhang, Juhui Qiu, Youhua Tan & Guixue Wang. (2020) The interplay of signaling pathway in endothelial cells—matrix stiffness dependency with targeted-therapeutic drugs. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:5, pages 165645.
Crossref
Crossref
Shipeng Zhan, Min Tang, Fang Liu, Peiyuan Xia, Maoqin Shu & Xiaojiao Wu. (2018) Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database of Systematic Reviews 2018:11.
Crossref
Crossref
Ivan Pećin, Merel L Hartgers, G Kees Hovingh, Ricardo Dent & Željko Reiner. (2017) Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology 24:13, pages 1383-1401.
Crossref
Crossref
Baishali M. Ambegaonkar, Diane Tipping, Adam B. Polis, Joanne E. Tomassini & Andrew M. Tershakovec. (2014) Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis 237:2, pages 829-837.
Crossref
Crossref
Wasem M. Alsabbagh, Joseph Dagenais, Lin Yan, Xinya Lu, Lisa M. Lix, Yvonne Shevchuk, Gary F. Teare & David F. Blackburn. (2014) Use and Misuse of Ezetimibe: Analysis of Use and Cost in Saskatchewan, a Canadian Jurisdiction With Broad Access. Canadian Journal of Cardiology 30:2, pages 237-243.
Crossref
Crossref
Zohara Sternberg, Trevor Chichelli, Daniel Sternberg, David Hojnacki, Allison Drake, Song Liu, Qiang Hu & Frederick Munschauer. (2013) Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis 231:2, pages 411-420.
Crossref
Crossref
Max Pichler, Dominik Lautsch, Claudia Adler, Karl Bögl, Heinz Drexel, Bernd Eber, Christiane Fauer, Johannes Föchterle, Bernhard Föger, Karin Gansch, Peter Grafinger, Monika Lechleitner, Bernhard Ludvik, Gerald Maurer, Reinhard Mörz, Bernhard Paulweber, Karl Peter Pfeiffer, Rudolf Prager, Gerhard Stark, Hermann Toplak, Otto Traindl & Raimund Weitgasser. (2013) Are there differences in LDL-C target value attainment in Austrian federal states? Yes!Gibt es Unterschiede in der LDL-Cholesterin Zielwerterreichung zwischen den Österreichischen Bundesländern? Ja!. Wiener Medizinische Wochenschrift 163:23-24, pages 528-535.
Crossref
Crossref
Paul Kah Hing Ling, Fernando Civeira, Andrei Gheorghe Dan, Mary E Hanson, Rachid Massaad, Celine Le Bailly De Tilleghem, Christopher Milardo & Joseph Triscari. (2012) Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in Health and Disease 11:1.
Crossref
Crossref
Galin V. Michailov, Glenn M. Davies & Karl J. Krobot. (2011) Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. The European Journal of Health Economics 13:3, pages 365-374.
Crossref
Crossref
John R GuytonD John Betteridge, Michel Farnier, Lawrence A Leiter, Jianxin Lin, Arvind Shah, Amy O Johnson-Levonas & Philippe Brudi. (2011) Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diabetes and Vascular Disease Research 8:2, pages 160-172.
Crossref
Crossref
F. L. J. Visseren. (2011) Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Netherlands Heart Journal 19:2, pages 59-60.
Crossref
Crossref
F. van Nooten, G. M. Davies, J. W. Jukema, A. H. Liem, E. Yap & X. H. Hu. (2011) Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Netherlands Heart Journal 19:2, pages 61-67.
Crossref
Crossref
John S. Sampalis, Stéphane Bissonnette & Stella Boukas. (2011) Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model. Advances in Preventive Medicine 2011, pages 1-7.
Crossref
Crossref
Carlo M Rotella, Augusto Zaninelli, Cristina Le Grazie, Mary E Hanson & Gian Franco Gensini. (2010) Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids in Health and Disease 9:1.
Crossref
Crossref
Gianluca Bardini, Carlo B Giorda, Antonio E Pontiroli, Cristina Le Grazie & Carlo M Rotella. (2010) Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovascular Diabetology 9:1.
Crossref
Crossref
John Reckless, Glenn Davies, Kaan Tunceli, X. Henry Hu & Philippe Brudi. (2010) Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. Value in Health 13:6, pages 726-734.
Crossref
Crossref
Kenta Okada, Hiroaki Yagyu, Kazuhiko Kotani, Michiaki Miyamoto, Jun-ichi Osuga, Shoichiro Nagasaka & Shun Ishibashi. (2010) Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocrine Journal 57:10, pages 903-908.
Crossref
Crossref
M. Farnier, M. Averna, L. Missault, H. Vaverkova, M. Viigimaa, R. Massaad, K. Vandormael, A. O. Johnson-Levonas & P. Brudi. (2009) Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice 63:4, pages 547-559.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:2, pages 189-202.
Crossref
Crossref
Paul Hamilton. (2009) Role of ezetimibe in the management of patients with atherosclerosis. Coronary Artery Disease 20:2, pages 169-174.
Crossref
Crossref
Arshag D Mooradian. (2009) Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology 5:3, pages 150-159.
Crossref
Crossref
Hye Eun YoonJoon Chang SongBok Jin HyoungHyeon Seok HwangSo Young LeeYoun Joo JeonBum Soon ChoiYong Soo KimChul Woo Yang. (2009) The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients. The Korean Journal of Internal Medicine 24:3, pages 233.
Crossref
Crossref